Two leading voices in the evolving landscape of type 1 diabetes research, Dr. Joshua Vieth, Senior Director of Research at Breakthrough T1D, and Becky Sulik, Director of Education at the Rocky Mountain Diabetes Center, feature in a new article examining how biomarkers are driving progress toward disease-modifying therapies that go beyond insulin replacement.
The piece highlights the importance of C-peptide as a surrogate endpoint and showcases collaborations with companies such as Diamyd Medical to accelerate precision immunotherapies.
Read the article here